Intensity Therapeutics, Inc. (INTS)
- Previous Close
3.2600 - Open
3.1550 - Bid --
- Ask --
- Day's Range
3.1550 - 3.3000 - 52 Week Range
2.0100 - 11.4400 - Volume
11,601 - Avg. Volume
12,328 - Market Cap (intraday)
46.562M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2400 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
14.33
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs in the United States. Its lead product candidate includes INT230-6, which is in human clinical studies for the treatment of refractory solid tumors, such as soft tissue sarcoma which is in phase 3 trails; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
www.intensitytherapeutics.comRecent News: INTS
View MorePerformance Overview: INTS
Trailing total returns as of 10/16/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: INTS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: INTS
View MoreValuation Measures
Market Cap
44.90M
Enterprise Value
38.72M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
8.40
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-72.74%
Return on Equity (ttm)
-147.23%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-15.07M
Diluted EPS (ttm)
-0.2400
Balance Sheet and Cash Flow
Total Cash (mrq)
6.32M
Total Debt/Equity (mrq)
2.83%
Levered Free Cash Flow (ttm)
9.66M